Strategic Approaches for Overcoming Peptide and Protein Drug Limitations

Area of Science:

• Pharmaceutical Science
• Biotechnology
• Drug Delivery

Background:

• Protein and peptide therapeutics offer high specificity but suffer from instability, short in vivo half-life, low bioavailability, and immunogenicity.
• These limitations hinder clinical efficacy, patient compliance, and market viability of protein drugs.

Purpose of the Study:

• To critically review the challenges associated with protein and peptide drugs.
• To present and evaluate current strategies for enhancing their clinical performance and market viability.

Main Methods:

• Review of literature on protein and peptide drug limitations and enhancement strategies.
• Detailed examination of PEGylation (random and site-specific), encapsulation in delivery systems, and biobetter approaches like site-directed mutagenesis.
• Analysis of market data and approved drug examples.

Main Results:

• PEGylation effectively improves protein stability, extends half-life, reduces immunogenicity, and optimizes pharmacokinetics.
• Polymeric and lipid-based delivery systems protect proteins from degradation, control release, and enhance absorption.
• Biobetter approaches, including mutagenesis, enhance protein stability and reduce immunogenicity.

Conclusions:

• Innovative strategies like PEGylation, advanced drug delivery, and bioengineering significantly improve the clinical performance of protein therapeutics.
• These advancements enhance drug efficacy, patient compliance, and the overall market success of protein-based medicines.